Several risk assessment scoring systems have been proposed to assess the therapeutic response and predict long term prognosis in ursodeoxycholic acid (UDCA)-treated primary biliary cholangitis (PBC) patients, in order to risk stratify PBC patients and guide their management. However there scoring systems have not been fully validated in Chinese population. This study is going to compare the prognostic ability of these criteria, validate the overseas scoring systems, develop and validate a new scoring system in a cohort of Chinese PBC patients.
Study Type
OBSERVATIONAL
Enrollment
57
Standard care of PBC patients
Centre of non-infectious liver diseases, Beijing 302 Hospital, Beijing, China.
Beijing, China
Liver related Death
Whether the patients die from liver-related causes during the follow-up
Time frame: During follow-up after a year of starting UDCA, an average of 1 year
Complications of cirrhosis
Whether the complication of cirrhosis i.e. ascites, hepatic encephalopathy, variceal bleeding occur during the follow-up
Time frame: During follow-up after a year of starting UDCA, an average of 1 year
Liver transplant
Whether the patients have liver transplant during the follow-up
Time frame: During follow-up after a year of starting UDCA, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.